As slower nicotine metabolism, due to less CYP2A6 enzyme activity, is associated with smoking fewer CPD [118], and lower smoking intensity [120], CYP2A6 activity variation may indirectly influence lung cancer risk through lowering smoking quantity and procarcinogen exposure. The gene discussed is CYP2A6; the disease is lung carcinoma.